gemcitabine

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-Hodgkin's Lymphoma

Conditions

Non-Hodgkin's Lymphoma, Marginal Zone Lymphoma

Trial Timeline

Jun 1, 2006 → Mar 1, 2009

NCT ID

NCT00337259

About gemcitabine

gemcitabine is a phase 2 stage product being developed by Eli Lilly for Non-Hodgkin's Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00337259. Target conditions include Non-Hodgkin's Lymphoma, Marginal Zone Lymphoma.

What happened to similar drugs?

6 of 20 similar drugs in Non-Hodgkin's Lymphoma were approved

Approved (6) Terminated (3) Active (11)

🔄Bortezomib + Rituximab + RituximabJohnson & JohnsonPhase 3

🔄Zoledronic Acid + Vitamin D + Calcium CarbonateNovartisPhase 3

❌Ofatumumab + Rituximab + Ofatumumab + RituximabNovartisPhase 3

🔄rituximab [MabThera/Rituxan] + Standard chemotherapyRochePhase 3

🔄rituximab [Mabthera/Rituxan]RochePhase 3

🔄Chemotherapy (Induction Period) + RituximabRochePhase 3

✅Chemotherapy + Immunochemotherapy + PegfilgrastimRocheApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00337259	Phase 2	Terminated	Jun 1, 2006	Mar 1, 2009	Non-Hodgkin's Lymphoma
NCT00191711	Phase 2	Completed	Feb 1, 2004	Oct 1, 2005	Superficial Bladder Cancer
NCT00191971	Phase 2	Completed	Jan 1, 2004	Sep 1, 2006	Urologic Neoplasms
NCT00390182	Phase 1/2	Completed	Oct 1, 2003	May 1, 2011	Gastrointestinal Neoplasms
NCT00491114	Phase 2	Completed	Jul 1, 2003	Aug 1, 2004	Bladder Neoplasms
NCT02046304	Phase 1	Completed	Dec 1, 2001	Mar 1, 2015	Sarcoma
NCT00146276	Phase 3	UNKNOWN	Jul 1, 2000	—	Bladder Cancer

Competing Products

20 competing products in Non-Hodgkin's Lymphoma

See all competitors

Product	Company	Stage	Hype Score
YM155 + Rituximab	Astellas Pharma	Phase 2	35
Tazemetostat	Eisai	Phase 2	35
ONTAK	Eisai	Phase 2	35
Tazemetostat	Eisai	Phase 1	29
ME-401	Kyowa Kirin	Phase 1	29
ME-401	Kyowa Kirin	Phase 2	39
gemcitabine + cisplatin + dexamethasone	Eli Lilly	Phase 2	35
LY317615	Eli Lilly	Phase 2	35
LY4584180 + Rituximab	Eli Lilly	Phase 1	36
Bortezomib + Rituximab + Rituximab	Johnson & Johnson	Phase 3	40
HRS-3738	Jiangsu Hengrui Medicine	Phase 1	25
SHR1459 ；YY-20394 + SHR1459 ；YY-20394 + Gemcitabine-Oxaliplatin	Jiangsu Hengrui Medicine	Phase 2	31
ABT-199 + Ketoconazole	AbbVie	Phase 1	29
ABT-199 + Rifampin	AbbVie	Phase 1	21
[14C]ABT-199 (GDC-0199)	AbbVie	Phase 1	21
ABT-199 + Rituximab + Bendamustine	AbbVie	Phase 1	29
ABBV-291	AbbVie	Phase 1	36
ABT-199	AbbVie	Phase 1	29
Avelumab	Merck	Phase 1	33
Pembrolizumab + Flt3L + Poly ICLC	Merck	Phase 1/2	28